Recent evidence indicates that patients with AD exhibit abnormal glycan profiles [62,63,64,65] and that many AD-associated molecules—beyond the key proteins APP and tau—are either glycosylated or involved in glycan regulation [66,67]. The gene discussed is MAPT; the disease is Alzheimer disease.